KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:开放图源暂不可得 入排置信度 0.98

Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary End Points From the EMBARK Trial.

Neal D Shore, Martin Gleave, Ugo De Giorgi, Antti Rannikko, Christopher M Pieczonka, Swetha Sridharan, Klaus Brasso, Henry H Woo, Antonio Gómez Caamaño, Jeff W Saranchuk, Luke T Nordquist, Ubirajara Ferreira, Yiyun Tang, Brad Rosbrook, Gabriel P Haas, Matt Rosales, Fabian Zohren, Jamal Tarazi, Stephen J Freedland

J Urol 215(5) 512-525

PMID41364813
PMCID-
DOI10.1097/JU.0000000000004890
发表日期2025-12-09
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

PURPOSE: The primary analysis of EMBARK reported improved metastasis-free survival for enzalutamide plus leuprolide (enzalutamide combination) vs leuprolide plus placebo (leuprolide alone) in patients with high-risk biochemical recurrence while maintaining quality of life. Here, we present secondary efficacy end points for enzalutamide combination vs leuprolide alone. MATERIALS AND METHODS: EMBARK is a global, multicenter, randomized, controlled, phase 3 trial. Patients were randomized (1:1:1) to enzalutamide combination, leuprolide alone, or enzalutamide monotherapy. Non-key secondary end points reported herein include time to distant metastasis, resumption of any hormonal therapy, castration resistance, symptomatic progression, and first symptomatic skeletal event. Hormonal treatment-related symptoms were assessed using the Quality-of-Life Questionnaire-Prostate 25. Time-to-event end points were summarized using the Kaplan-Meier method, with nominal P values. RESULTS: Enzalutamide combination vs leuprolide alone was associated with increased 5-year probabilities (95% CI) for remaining free of distant metastasis (91.0% [87.1-93.7] vs 81.5% [76.3-85.7]), resumption of any hormonal therapy after treatment suspension (14.9% [10.8-19.6] vs 7.8% [4.4-12.3]), castration resistance (96.6% [93.9-98.1] vs 67.8% [62.4-72.6]), symptomatic progression (70.9% [65.5-75.6] vs 53.3% [47.6-58.6]), and first symptomatic skeletal event (97.8% [95.4-98.9] vs 91.5% [87.8-94.1]). Time to confirmed clinically meaningful deterioration of hormonal treatment-related symptoms favored leuprolide alone vs enzalutamide combination, although the median difference was small (0.03 months). CONCLUSIONS: Combined with the primary findings from EMBARK, data from non-key secondary efficacy end points strengthen support for enzalutamide combination as a new standard of care for patients with high-risk biochemical recurrence. CLINICAL TRIAL REGISTRATION NUMBER: NCT02319837.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。